keyword
MENU ▼
Read by QxMD icon Read
search

CALGB

keyword
https://www.readbyqxmd.com/read/29093755/unique-amplification-of-bcr-abl1-gene-fusion-in-a-case-of-t-cell-acute-lymphoblastic-leukemia
#1
Rima Koka, Najeebah A Bade, Edward A Sausville, Yi Ning, Ying Zou
Background: ABL1 gene translocations can be seen in precursor T-acute lymphoblastic leukemia (T-ALL). The typical translocation partner is the NUP214 gene. BCR-ABL translocations are relatively rare in this entity. Furthermore, while there have been unique patterns of amplification noted among the NUP214-ABL fusion genes, there have been few such reports among cases with BCR-ABL fusion genes. Case presentation: Here we report a unique case of a 44-year old patient with T-ALL in which the blasts demonstrated a derivative chromosome 9 involving a 9;22 translocation and a dicentric Philadelphia chromosome 22 with a homogeneously staining region at the interface of the 9;22 translocation, leading to BCR-ABL1 gene amplification...
2017: Molecular Cytogenetics
https://www.readbyqxmd.com/read/29034366/a-phase-2-study-incorporating-sorafenib-into-the-chemotherapy-for-older-adults-with-flt3-mutated-acute-myeloid-leukemia-calgb-11001
#2
Geoffrey L Uy, Sumithra J Mandrekar, Kristina Laumann, Guido Marcucci, Weiqiang Zhao, Mark J Levis, Heidi D Klepin, Maria R Baer, Bayard L Powell, Peter Westervelt, Daniel J DeAngelo, Wendy Stock, Ben Sanford, William G Blum, Clara D Bloomfield, Richard M Stone, Richard A Larson
The Cancer and Leukemia Group B (CALGB), now part of the Alliance for Clinical Trials in Oncology, conducted a multicenter, single-arm, phase 2 study in patients ≥60 years with FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia (AML). In this study, sorafenib was added to daunorubicin and cytarabine-based induction and consolidation chemotherapy and was also continued for 12 months of maintenance therapy. The primary end point of the study was overall survival (OS) at 1 year in the FLT3 internal tandem duplication (FLT3-ITD) cohort...
January 24, 2017: Blood Advances
https://www.readbyqxmd.com/read/29023215/cost-effectiveness-analysis-of-monthly-zoledronic-acid-zoledronic-acid-every-3-months-and-monthly-denosumab-in-women-with-breast-cancer-and-skeletal-metastases-calgb-70604-alliance
#3
Charles L Shapiro, James P Moriarty, Stacie Dusetzina, Andrew L Himelstein, Jared C Foster, Stephen S Grubbs, Paul J Novotny, Bijan J Borah
Purpose Skeletal-related events (SREs) such as pathologic fracture, spinal cord compression, or the necessity for radiation or surgery to bone metastasis cause considerable morbidity, decrements in quality of life, and costs to the health care system. The results of a recent large randomized trial (Cancer and Leukemia Group B/Alliance for Clinical Trials in Oncology [CALGB/Alliance 70604]) showed that zoledronic acid (ZA) every 3 months was noninferior to monthly ZA in reducing the risks of SREs. We sought to determine the cost-effectiveness (CE) of monthly ZA, ZA every 3 months, and monthly denosumab in women with breast cancer and skeletal metastases...
October 12, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28982874/impact-of-calgb-9343-trial-and-sociodemographic-variation-on-patterns-of-adjuvant-radiation-therapy-practice-for-elderly-women-%C3%A2-70-years-with-stage-i-estrogen-receptor-positive-breast-cancer-analysis-of-the-national-cancer-data-base
#4
Quyen D Chu, Meijiao Zhou, Kaelen L Medeiros, Prakash Peddi, Xiao Cheng Wu
BACKGROUND: The Cancer and Leukemia Group B (CALGB) 9343 trial demonstrated that adjuvant radiation therapy (RT) can be omitted in women 70 years or older, with small (≤2 cm), negative lymph nodes, estrogen receptor (ER)-positive breast cancer. We examined whether RT usage following the CALGB publication had decreased over time and evaluated sociodemographic and clinical factors associated with RT omission. MATERIALS AND METHODS: From the National Cancer Data Base, we analyzed a cohort of 120,308 women aged 70 years or older with stage I, ER-positive breast cancer who underwent lumpectomy...
October 2017: Anticancer Research
https://www.readbyqxmd.com/read/28976791/adjuvant-chemoradiotherapy-with-epirubicin-cisplatin-and-fluorouracil-compared-with-adjuvant-chemoradiotherapy-with-fluorouracil-and-leucovorin-after-curative-resection-of-gastric-cancer-results-from-calgb-80101-alliance
#5
RANDOMIZED CONTROLLED TRIAL
Charles S Fuchs, Donna Niedzwiecki, Harvey J Mamon, Joel E Tepper, Xing Ye, Richard S Swanson, Peter C Enzinger, Daniel G Haller, Tomislav Dragovich, Steven R Alberts, Georg A Bjarnason, Christopher G Willett, Leonard L Gunderson, Richard M Goldberg, Alan P Venook, David Ilson, Eileen O'Reilly, Kristen Ciombor, David J Berg, Jeffrey Meyerhardt, Robert J Mayer
Purpose After curative resection of gastric or gastroesophageal junction adenocarcinoma, Intergroup Trial 0116 (Phase III trial of postoperative adjuvant radiochemotherapy for high risk gastric and gastroesophageal junction adenocarcinoma: Demonstrated superior survival for patients who received postoperative chemoradiotherapy with bolus fluorouracil (FU) and leucovorin (LV) compared with surgery alone. CALGB 80101 (Alliance; Phase III Intergroup Trial of Adjuvant Chemoradiation After Resection of Gastric or Gastroesophageal Adenocarcinoma) assessed whether a postoperative chemoradiotherapy regimen that replaced FU plus LV with a potentially more active systemic therapy could further improve overall survival...
November 10, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28945884/a-phase-ii-trial-of-lenalidomide-plus-rituximab-in-previously-untreated-follicular-non-hodgkin-s-lymphoma-nhl-calgb-50803-alliance
#6
P Martin, S-H Jung, B Pitcher, N L Bartlett, K A Blum, T Shea, E D Hsi, J Ruan, S E Smith, J P Leonard, B D Cheson
Background: This multicenter, phase II trial tested the tolerability and efficacy of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma (FL). Patients and methods: Patients with grade 1-3a FL, stage 3-4 or bulky stage 2, FL international prognostic index (FLIPI) 0-2, and no prior therapy were eligible to receive rituximab 375 mg/m2 weekly during cycle 1 and day 1 of cycles 4, 6, 8, and 10, plus lenalidomide 20-25 mg on days 1-21 for twelve 28-day cycles...
November 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28842510/impact-of-therapy-on-genomics-and-transcriptomics-in-high-risk-prostate-cancer-treated-with-neoadjuvant-docetaxel-and-androgen-deprivation-therapy
#7
Himisha Beltran, Alexander W Wyatt, Edmund C Chedgy, Adam Donoghue, Matti Annala, Evan W Warner, Kevin Beja, Michael Sigouros, Fan Mo, Ladan Fazli, Colin C Collins, James Eastham, Michael Morris, Mary-Ellen Taplin, Andrea Sboner, Susan Halabi, Martin E Gleave
Purpose: The combination of docetaxel chemotherapy and androgen deprivation therapy (ADT) has become a standard treatment for patients with metastatic prostate cancer. The recently accrued phase III CALGB 90203 trial was designed to investigate the clinical effectiveness of this treatment approach earlier in the disease. Specimens from this trial offer a unique opportunity to interrogate the acute molecular response to docetaxel and ADT and identify potential biomarkers.Experimental Design: We evaluated baseline clinical data, needle biopsies, and radical prostatectomy (RP) specimens from 52 (of 788) patients enrolled on CALGB 90203 at one high volume center...
November 15, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28826617/updated-analysis-of-calgb-alliance-100104
#8
Mario Boccadoro
No abstract text is available yet for this article.
September 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28826616/updated-analysis-of-calgb-alliance-100104-assessing-lenalidomide-versus-placebo-maintenance-after-single-autologous-stem-cell-transplantation-for-multiple-myeloma-a-randomised-double-blind-phase-3-trial
#9
Sarah A Holstein, Sin-Ho Jung, Paul G Richardson, Craig C Hofmeister, David D Hurd, Hani Hassoun, Sergio Giralt, Edward A Stadtmauer, Daniel J Weisdorf, Ravi Vij, Jan S Moreb, Natalie S Callander, Koen van Besien, Teresa G Gentile, Luis Isola, Richard T Maziarz, Asad Bashey, Heather Landau, Thomas Martin, Muzaffar H Qazilbash, Cesar Rodriguez, Brian McClune, Robert L Schlossman, Scott E Smith, Vera Hars, Kouros Owzar, Chen Jiang, Molly Boyd, Chelsea Schultz, Marcia Wilson, Parameswaran Hari, Marcelo C Pasquini, Mary M Horowitz, Thomas C Shea, Steven M Devine, Charles Linker, Kenneth C Anderson, Philip L McCarthy
BACKGROUND: In the CALGB (Alliance) 100104 study, lenalidomide versus placebo after autologous stem-cell transplantation (ASCT) was investigated for patients with newly diagnosed myeloma. That study showed improved time to progression and overall survival and an increase in second primary malignancies for lenalidomide at a median follow-up of 34 months. Here we report an updated intention-to-treat analysis of CALGB (Alliance) 100104 at a median follow-up of 91 months. METHODS: Patients were eligible for this randomised, double-blind, placebo-controlled, phase 3 trial if they had symptomatic disease requiring treatment; had received, at most, two induction regimens; and had achieved stable disease or better in the first 100 days after ASCT...
September 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28791622/lenalidomide-a-review-in-newly-diagnosed-multiple-myeloma-as-maintenance-therapy-after-asct
#10
Yahiya Y Syed
Lenalidomide (Revlimid(®)) is an immunomodulatory drug with multiple mechanisms of action against multiple myeloma. It is a thalidomide analogue, with improved potency and reduced toxicity compared with thalidomide. In the EU and USA, lenalidomide monotherapy is indicated for the maintenance treatment of patients with newly diagnosed multiple myeloma who have undergone autologous stem-cell transplantation (ASCT). In the pivotal, phase 3 IFM 2005-02 and CALGB 100104 trials, lenalidomide maintenance therapy after ASCT administered until disease progression significantly prolonged progression-free survival (PFS; primary endpoint) relative to placebo in patients with newly diagnosed multiple myeloma...
September 2017: Drugs
https://www.readbyqxmd.com/read/28653250/cognitive-function-and-discontinuation-of-adjuvant-hormonal-therapy-in-older-breast-cancer-survivors-calgb-369901-alliance
#11
Shirley M Bluethmann, Catherine M Alfano, Jonathan D Clapp, George Luta, Brent J Small, Arti Hurria, Harvey J Cohen, Steven Sugarman, Hyman B Muss, Claudine Isaacs, Jeanne S Mandelblatt
PURPOSE: To investigate the effects of cognitive function on discontinuation of hormonal therapy in breast cancer survivors ages 65+ ("older"). METHODS: Older breast cancer survivors with invasive, non-metastatic disease, and no reported cognitive difficulties were recruited from 78 Alliance sites between 2004 and 2011. Eligible survivors (n = 1280) completed baseline interviews; follow-up was conducted annually for up to 7 years. Survivors with estrogen-receptor-positive (ER+) cancers who initiated hormonal therapy (n = 990) were included...
June 26, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28620884/kinetic-pharmacodynamic-model-of-chemotherapy-induced-peripheral-neuropathy-in-patients-with-metastatic-breast-cancer-treated-with-paclitaxel-nab-paclitaxel-or-ixabepilone-calgb-40502-alliance
#12
Shailly Mehrotra, Manish R Sharma, Elizabeth Gray, Kehua Wu, William T Barry, Clifford Hudis, Eric P Winer, Alan P Lyss, Deborah L Toppmeyer, Alvaro Moreno-Aspitia, Thomas E Lad, Mario Valasco, Beth Overmoyer, Hope Rugo, Mark J Ratain, Jogarao V Gobburu
Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting toxicity caused by several chemotherapeutic agents. Currently, CIPN is managed by empirical dose modifications at the discretion of the treating physician. The goal of this research is to quantitate the dose-CIPN relationship to inform the optimal strategies for dose modification. Data were obtained from the Cancer and Leukemia Group B (CALGB) 40502 trial, a randomized phase III trial of paclitaxel vs. nab-paclitaxel vs. ixabepilone as first-line chemotherapy for locally recurrent or metastatic breast cancer...
June 15, 2017: AAPS Journal
https://www.readbyqxmd.com/read/28611204/clinical-and-genome-wide-analysis-of-cisplatin-induced-peripheral-neuropathy-in-survivors-of-adult-onset-cancer
#13
M Eileen Dolan, Omar El Charif, Heather E Wheeler, Eric R Gamazon, Shirin Ardeshir-Rouhani-Fard, Patrick Monahan, Darren R Feldman, Robert J Hamilton, David J Vaughn, Clair J Beard, Chunkit Fung, Jeri Kim, Sophie D Fossa, Daniel L Hertz, Taisei Mushiroda, Michiaki Kubo, Lawrence H Einhorn, Nancy J Cox, Lois B Travis
Purpose: Our purpose was to characterize the clinical influences, genetic risk factors, and gene mechanisms contributing to persistent cisplatin-induced peripheral neuropathy (CisIPN) in testicular cancer survivors (TCSs).Experimental Design: TCS given cisplatin-based therapy completed the validated EORTC QLQ-CIPN20 questionnaire. An ordinal CisIPN phenotype was derived, and associations with age, smoking, excess drinking, hypertension, body mass index, diabetes, hypercholesterolemia, cumulative cisplatin dose, and self-reported health were examined for 680 TCS...
October 1, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28602413/the-use-of-hormone-therapy-alone-versus-hormone-therapy-and-radiation-therapy-for-breast-cancer-in-elderly-women-a-population-based-study
#14
COMPARATIVE STUDY
Alan M Nichol, Elisa K Chan, Sarah Lucas, Sally L Smith, Lovedeep Gondara, Caroline Speers, Scott Tyldesley
PURPOSE: The Cancer and Leukemia Group B (CALGB) 9343 trial randomized elderly women with estrogen receptor-positive, stage 1 breast cancer to receive either hormone therapy (HT) or HT and radiation therapy (HT-RT) after lumpectomy and showed no difference in survival. After this publication, a practice guideline made HT alone a standard treatment option in British Columbia. The subsequent population-based pattern of practice was studied. METHODS AND MATERIALS: All women aged 70 to 79 years, referred after lumpectomy from 1999 to 2009, with stage 1, estrogen receptor-positive breast cancer were identified...
July 15, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28586968/final-results-of-a-phase-3-trial-of-celecoxib-c-in-addition-to-standard-chemotherapy-for-advanced-non-small-cell-lung-cancer-with-cox-2-overexpression-calgb-30801-alliance
#15
M J Edelman, X Wang, L Hodgson, R T Cheney, M Q Baggstrom, T Sachdev, A Gajra, E M Bertino, K L Reckamp, J Molina, J Schiller, K Mitchell-Edwards, P Friedman, J Ritter, G Milne, T E Stinchcombe, O Hahn, E E Vokes
No abstract text is available yet for this article.
May 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28577080/receptor-activator-of-nuclear-factor-kappa-b-rank-expression-in-primary-breast-cancer-correlates-with-recurrence-free-survival-and-development-of-bone-metastases-in-i-spy1-calgb-150007-150012-acrin-6657
#16
Neelima Vidula, Christina Yau, Jiali Li, Laura J Esserman, Hope S Rugo
PURPOSE: The receptor activator of nuclear factor kappa B (RANK)/RANK ligand (RANKL)/osteoprotegerin (OPG) axis may contribute to the development of bone metastases (BM). We studied gene expression in this pathway in primary breast cancer (BC) to determine correlations with clinical characteristics and outcomes in the neoadjuvant I-SPY1 study. METHODS: We evaluated RANK/RANKL/OPG expression using expression microarrays in I-SPY1 (n = 149). Associations with clinical features were determined using t test and ANOVA...
August 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28577078/comparison-of-residual-cancer-burden-american-joint-committee-on-cancer-staging-and-pathologic-complete-response-in-breast-cancer-after-neoadjuvant-chemotherapy-results-from-the-i-spy-1-trial-calgb-150007-150012-acrin-6657
#17
Jeffrey I Campbell, Christina Yau, Polina Krass, Dan Moore, Lisa A Carey, Alfred Au, David Chhieng, Dilip Giri, Chad Livasy, Carolyn Mies, Joseph Rabban, Venetia R Sarode, Baljit Singh, Laura Esserman, Yunn-Yi Chen
PURPOSE: Several pathologic staging systems characterize residual tumor in patients undergoing neoadjuvant chemotherapy for breast cancer. Pathologic complete response (pCR) is now accepted by the Food and Drug Administration as an endpoint for granting accelerated drug approval. Two other systems of post-neoadjuvant pathologic tumor staging-residual cancer burden (RCB) and the American Joint Committee on Cancer post-neoadjuvant therapy staging system (yAJCC)-have been developed to characterize residual tumors when patients do not achieve pCR...
August 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28489511/phase-iii-randomized-placebo-controlled-double-blind-trial-of-celecoxib-in-addition-to-standard-chemotherapy-for-advanced-non-small-cell-lung-cancer-with-cyclooxygenase-2-overexpression-calgb-30801-alliance
#18
RANDOMIZED CONTROLLED TRIAL
Martin J Edelman, Xiaofei Wang, Lydia Hodgson, Richard T Cheney, Maria Q Baggstrom, Sachdev P Thomas, Ajeet Gajra, Erin Bertino, Karen L Reckamp, Julian Molina, Joan H Schiller, Kisha Mitchell-Richards, Paula N Friedman, Jon Ritter, Ginger Milne, Olwen M Hahn, Thomas E Stinchcombe, Everett E Vokes
Purpose Tumor overexpression of cyclooxygenase-2 (COX-2) has been associated with worse outcome in non-small-cell lung cancer (NSCLC). In Cancer and Leukemia Group B (CALGB) 30203, we found that the selective COX-2 inhibitor celecoxib in addition to chemotherapy in advanced NSCLC improved progression-free and overall survival in patients with moderate to high COX-2 expression by immunohistochemistry (IHC). CALGB 30801 (Alliance) was designed to prospectively confirm that finding. Patients and Methods Patients with NSCLC (stage IIIB with pleural effusion or stage IV according to American Joint Committee on Cancer [sixth edition] criteria) were preregistered, and biopsy specimens were analyzed for COX-2 by IHC...
July 1, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28437029/men-s-eating-and-living-meal-study-calgb-70807-alliance-recruitment-feasibility-and-baseline-demographics-of-a-randomized-trial-of-diet-in-men-on-active-surveillance-for-prostate-cancer
#19
J Kellogg Parsons, John P Pierce, James Mohler, Electra Paskett, Sin-Ho Jung, Michael J Morris, Eric Small, Olwen Hahn, Peter Humphrey, John Taylor, James Marshall
OBJECTIVE: To assess the feasibility of performing national, randomized trials of dietary interventions for localized prostate cancer. METHODS: The Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]) is a phase III clinical trial testing the efficacy of a high-vegetable diet to prevent progression in patients with prostate cancer on active surveillance (AS). Participants were randomized to a validated diet counselling intervention or to a control condition...
April 24, 2017: BJU International
https://www.readbyqxmd.com/read/28407110/prognostic-and-predictive-value-of-primary-tumour-side-in-patients-with-ras-wild-type-metastatic-colorectal-cancer-treated-with-chemotherapy-and-egfr-directed-antibodies-in-six-randomized-trials
#20
D Arnold, B Lueza, J-Y Douillard, M Peeters, H-J Lenz, A Venook, V Heinemann, E Van Cutsem, J-P Pignon, J Tabernero, A Cervantes, F Ciardiello
Background: There is increasing evidence that metastatic colorectal cancer (mCRC) is a genetically heterogeneous disease and that tumours arising from different sides of the colon (left versus right) have different clinical outcomes. Furthermore, previous analyses comparing the activity of different classes of targeted agents in patients with KRAS wild-type (wt) or RAS wt mCRC suggest that primary tumour location (side), might be both prognostic and predictive for clinical outcome. Methods: This retrospective analysis investigated the prognostic and predictive influence of the localization of the primary tumour in patients with unresectable RAS wt mCRC included in six randomized trials (CRYSTAL, FIRE-3, CALGB 80405, PRIME, PEAK and 20050181), comparing chemotherapy plus EGFR antibody therapy (experimental arm) with chemotherapy or chemotherapy and bevacizumab (control arms)...
August 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
keyword
keyword
13247
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"